摘要
原发性肝癌是常见的恶性实体肿瘤，是我国第2位的癌症杀手，是全球第3位癌症死因。近年来，肝癌基础研究领域进展迅速，已发现了大量与肝癌发生、发展相关的分子标记物及信号通路。但是，在临床治疗中，肝癌患者的5年生存率并未显著提高。这主要还是由于早期诊断率低并且缺乏非常有效的治疗手段。临床结果及基础研究间的矛盾似乎需要发展转化医学来解决。转化医学以B2B的模式来沟通基础研究与临床医学实践：即建立从实验室到临床，再从临床到实验室的循环。基础研究的发现及理论可以在临床实践中来检验；而从临床获得的信息可以再通过基础研究来精炼，以便更好地理解疾病的生物学特征。在肝癌中，分子诊断标记物的筛选、分子分型及个体化靶向药物的发展是转化医学中非常重要的领域。转化医学的发展将沟通基础研究及临床实践，不但可以提高对肝癌发生、发展相关分子机制的理解，而且将促进肝癌临床治疗的发展及进步。
Primary liver cancer is the third most common cause of death from cancer worldwide, and it is the second cause of cancer death in China. A variety of molecular markers and signaling pathways associated with hepatocarci nogenesis and tumor progression have been discovered in basic research in the recent decade. However, the 5 year survival of patients has not been remarkably improved, due in a large part to the late diagnosis and the limited treatment options. It seems that translational medicine should be accel erated to addres this problem. Translational medicine has been shown to bridge basic research and clinical practice in a B2B model： from bench to the bedside and bedside to the bench. It goes from the bench to bedside where theories e merging from preclinical experimentation are tested on patients, and from bedside to the bench, where information obtained from preliminary clinical sciences is used to refine the understanding of the biological principles. In liver cancer, diagnostic markers screening, development of molecular classification, and stratifying patients for targeted therapy are considered as exciting fields of translational medicine. The integration of basic and clinical sciences by translational medicine will improve not only the understanding of the underlying molecular mechanisms, but also the clinical outcomes in patients with primary liver cancer.
出处
《中华肝胆外科杂志》
CAS
CSCD
北大核心
2011年第5期357-358,共2页
Chinese Journal of Hepatobiliary Surgery
关键词
原发性肝癌
转化医学
临床结果
Primary liver cancer
Translational medicine
Clinical outcome
